knowledge -WSS

knowledge

author：knowledge 2025-09-02 08:11:48 - browse：687

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Fetal cell organoids grown from amniotic fluid, study finds

WSS

Readout Newsletter: BridgeBio, Akero, and human embryo models

Streamlined flu vaccines recommended by FDA advisory panel

Scientists successfully use ultrasound imaging to map brain activity

Stigma and the return of syphilis

Insmed lung disease drug hits target in key Phase 3 trial

Antibiotic resistance nearly killed me, so I'm raising awareness of it

hotspot

knowledge

explore

Hepatitis C has a cure — but many Americans still lack access to it

Stem cell biologist probes earliest stages of human development

Moonlake's readout produced a cash windfall. Risks remain

Stigma and the return of syphilis

Novavax promises a turnaround & Lilly roils the obesity market

Startling documents reveal new facets of Sacklers' opioid empire

How to save PrEP access — and even expand it

Immune cells and nerve overgrowth may explain recurring UTI pain

Medical leaders decry Supreme Court decision on affirmative action

Fetal cell organoids grown from amniotic fluid, study finds

Wikipedia

A new approach to psychiatric drug development

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Insmed lung disease drug hits target in key Phase 3 trial

Florida health officials providing scant details on measles cases

Insmed lung disease drug hits target in key Phase 3 trial

iTeos Therapeutics debuts first data on TIGIT

entertainment

Wikipedia

leisure time

entertainment